Standard
Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial. / Rasmussen, Klaus; Maeng, Michael; Kaltoft, Anne; Thayssen, Per; Kelbaek, Henning; Tilsted, Hans Henrik; Abildgaard, Ulrik; Christiansen, Evald Høj; Engstrøm, Thomas; Krusell, Lars Romer; Ravkilde, Jan; Hansen, Peter Riis; Hansen, Knud Nørregaard; Abildstrøm, Steen Zabell; Aarøe, Jens; Jensen, Jan Skov; Kristensen, Steen Dalby; Bøtker, Hans Erik; Madsen, Morten; Johnsen, Søren Paaske; Jensen, Lisette Okkels; Sørensen, Henrik Toft; Thuesen, Leif; Lassen, Jens Flensted; SORT OUT III study group.
I:
Lancet, Bind 375, Nr. 9720, 27.03.2010, s. 1090-9.
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
Rasmussen, K, Maeng, M, Kaltoft, A, Thayssen, P, Kelbaek, H, Tilsted, HH, Abildgaard, U, Christiansen, EH
, Engstrøm, T, Krusell, LR, Ravkilde, J
, Hansen, PR, Hansen, KN, Abildstrøm, SZ, Aarøe, J, Jensen, JS, Kristensen, SD, Bøtker, HE, Madsen, M, Johnsen, SP, Jensen, LO, Sørensen, HT, Thuesen, L, Lassen, JF & SORT OUT III study group 2010, '
Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial',
Lancet, bind 375, nr. 9720, s. 1090-9.
https://doi.org/10.1016/S0140-6736(10)60208-5APA
Rasmussen, K., Maeng, M., Kaltoft, A., Thayssen, P., Kelbaek, H., Tilsted, H. H., Abildgaard, U., Christiansen, E. H.
, Engstrøm, T., Krusell, L. R., Ravkilde, J.
, Hansen, P. R., Hansen, K. N., Abildstrøm, S. Z., Aarøe, J., Jensen, J. S., Kristensen, S. D., Bøtker, H. E., Madsen, M., ... SORT OUT III study group (2010).
Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial.
Lancet,
375(9720), 1090-9.
https://doi.org/10.1016/S0140-6736(10)60208-5Vancouver
Rasmussen K, Maeng M, Kaltoft A, Thayssen P, Kelbaek H, Tilsted HH o.a.
Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial.
Lancet. 2010 mar. 27;375(9720):1090-9.
https://doi.org/10.1016/S0140-6736(10)60208-5Author
Rasmussen, Klaus ; Maeng, Michael ; Kaltoft, Anne ; Thayssen, Per ; Kelbaek, Henning ; Tilsted, Hans Henrik ; Abildgaard, Ulrik ; Christiansen, Evald Høj ; Engstrøm, Thomas ; Krusell, Lars Romer ; Ravkilde, Jan ; Hansen, Peter Riis ; Hansen, Knud Nørregaard ; Abildstrøm, Steen Zabell ; Aarøe, Jens ; Jensen, Jan Skov ; Kristensen, Steen Dalby ; Bøtker, Hans Erik ; Madsen, Morten ; Johnsen, Søren Paaske ; Jensen, Lisette Okkels ; Sørensen, Henrik Toft ; Thuesen, Leif ; Lassen, Jens Flensted ; SORT OUT III study group. / Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial. I: Lancet. 2010 ; Bind 375, Nr. 9720. s. 1090-9.
Bibtex
@article{d0f91538878a48238708b5656d451088,
title = "Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial",
abstract = "In low-risk patients, the zotarolimus-eluting stent has been shown to reduce rates of restenosis without increasing the risk of stent thrombosis. We compared the efficacy and safety of the zotarolimus-eluting stent versus the sirolimus-eluting stent in patients with coronary artery disease who were receiving routine clinical care with no direct follow-up.",
author = "Klaus Rasmussen and Michael Maeng and Anne Kaltoft and Per Thayssen and Henning Kelbaek and Tilsted, {Hans Henrik} and Ulrik Abildgaard and Christiansen, {Evald H{\o}j} and Thomas Engstr{\o}m and Krusell, {Lars Romer} and Jan Ravkilde and Hansen, {Peter Riis} and Hansen, {Knud N{\o}rregaard} and Abildstr{\o}m, {Steen Zabell} and Jens Aar{\o}e and Jensen, {Jan Skov} and Kristensen, {Steen Dalby} and B{\o}tker, {Hans Erik} and Morten Madsen and Johnsen, {S{\o}ren Paaske} and Jensen, {Lisette Okkels} and S{\o}rensen, {Henrik Toft} and Leif Thuesen and Lassen, {Jens Flensted} and Jensen, {Jan Skov}",
note = "Copyright 2010 Elsevier Ltd. All rights reserved.",
year = "2010",
month = mar,
day = "27",
doi = "http://dx.doi.org/10.1016/S0140-6736(10)60208-5",
language = "English",
volume = "375",
pages = "1090--9",
journal = "The Lancet",
issn = "0140-6736",
publisher = "TheLancet Publishing Group",
number = "9720",
}
RIS
TY - JOUR
T1 - Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial
AU - Rasmussen, Klaus
AU - Maeng, Michael
AU - Kaltoft, Anne
AU - Thayssen, Per
AU - Kelbaek, Henning
AU - Tilsted, Hans Henrik
AU - Abildgaard, Ulrik
AU - Christiansen, Evald Høj
AU - Engstrøm, Thomas
AU - Krusell, Lars Romer
AU - Ravkilde, Jan
AU - Hansen, Peter Riis
AU - Hansen, Knud Nørregaard
AU - Abildstrøm, Steen Zabell
AU - Aarøe, Jens
AU - Jensen, Jan Skov
AU - Kristensen, Steen Dalby
AU - Bøtker, Hans Erik
AU - Madsen, Morten
AU - Johnsen, Søren Paaske
AU - Jensen, Lisette Okkels
AU - Sørensen, Henrik Toft
AU - Thuesen, Leif
AU - Lassen, Jens Flensted
AU - SORT OUT III study group
N1 - Copyright 2010 Elsevier Ltd. All rights reserved.
PY - 2010/3/27
Y1 - 2010/3/27
N2 - In low-risk patients, the zotarolimus-eluting stent has been shown to reduce rates of restenosis without increasing the risk of stent thrombosis. We compared the efficacy and safety of the zotarolimus-eluting stent versus the sirolimus-eluting stent in patients with coronary artery disease who were receiving routine clinical care with no direct follow-up.
AB - In low-risk patients, the zotarolimus-eluting stent has been shown to reduce rates of restenosis without increasing the risk of stent thrombosis. We compared the efficacy and safety of the zotarolimus-eluting stent versus the sirolimus-eluting stent in patients with coronary artery disease who were receiving routine clinical care with no direct follow-up.
U2 - http://dx.doi.org/10.1016/S0140-6736(10)60208-5
DO - http://dx.doi.org/10.1016/S0140-6736(10)60208-5
M3 - Journal article
VL - 375
SP - 1090
EP - 1099
JO - The Lancet
JF - The Lancet
SN - 0140-6736
IS - 9720
ER -
